VRCA Verrica Pharmaceuticals Inc
Price (delayed)
$1.89
Market cap
$80.64M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.89
Enterprise value
$95.02M
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica's late-stage product candidate, VP-102, is in development to treat molluscum contagiosum (molluscum), common warts and
Highlights
Verrica Pharmaceuticals's gross profit has soared by 65% from the previous quarter and by 43% YoY
The revenue has surged by 62% year-on-year and by 56% since the previous quarter
The gross margin has decreased by 12% YoY but it has increased by 6% from the previous quarter
The equity has dropped by 124% year-on-year
The quick ratio has plunged by 78% YoY and by 28% from the previous quarter
Key stats
What are the main financial stats of VRCA
Market
Valuations
Earnings
Shares outstanding
42.67M
Market cap
$80.64M
Enterprise value
$95.02M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
6.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.83
Revenue
$13.91M
EBIT
-$78.28M
EBITDA
-$77.18M
Free cash flow
-$65.93M
Per share
Balance sheet
Liquidity
EPS
-$1.89
Free cash flow per share
-$1.42
Book value per share
-$0.31
Revenue per share
$0.3
TBVPS
$1.12
Total assets
$52.01M
Total liabilities
$65.31M
Debt
$46.31M
Equity
-$13.3M
Working capital
$27.27M
Debt to equity
-3.48
Current ratio
2.36
Quick ratio
2.1
Net debt/EBITDA
-0.19
Margins
Efficiency
Dividend
EBITDA margin
-555%
Gross margin
84%
Net margin
-625.1%
Operating margin
-581.4%
Return on assets
-117.1%
Return on equity
-691.7%
Return on invested capital
-177.3%
Return on capital employed
-245%
Return on sales
-562.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VRCA stock price
How has the Verrica Pharmaceuticals stock price performed over time
Intraday
-4.06%
1 week
-1.05%
1 month
-32.5%
1 year
-53.33%
YTD
-74.18%
QTD
-74.07%
Financial performance
How have Verrica Pharmaceuticals's revenue and profit performed over time
Revenue
$13.91M
Gross profit
$11.69M
Operating income
-$80.86M
Net income
-$86.93M
Gross margin
84%
Net margin
-625.1%
VRCA's net margin has shrunk by 130% YoY but it is up by 31% QoQ
Verrica Pharmaceuticals's operating margin has plunged by 113% YoY but it has increased by 33% from the previous quarter
Verrica Pharmaceuticals's gross profit has soared by 65% from the previous quarter and by 43% YoY
The revenue has surged by 62% year-on-year and by 56% since the previous quarter
Growth
What is Verrica Pharmaceuticals's growth rate over time
Valuation
What is Verrica Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
6.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.83
The EPS is down by 7% since the previous quarter
The equity has dropped by 124% year-on-year
The stock's price to sales (P/S) is 85% less than its last 4 quarters average of 44.0
The revenue has surged by 62% year-on-year and by 56% since the previous quarter
Efficiency
How efficient is Verrica Pharmaceuticals business performance
The return on assets has dropped by 181% year-on-year and by 11% since the previous quarter
The ROE has plunged by 155% from the previous quarter
The ROS has dropped by 107% year-on-year but it is up by 33% since the previous quarter
The return on invested capital has increased by 36% year-on-year and by 21% since the previous quarter
Dividends
What is VRCA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VRCA.
Financial health
How did Verrica Pharmaceuticals financials performed over time
Verrica Pharmaceuticals's total assets is 20% lower than its total liabilities
The quick ratio has plunged by 78% YoY and by 28% from the previous quarter
Verrica Pharmaceuticals's current ratio has shrunk by 76% YoY and by 26% QoQ
The equity has dropped by 124% year-on-year
Verrica Pharmaceuticals's debt to equity has plunged by 111% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.